UBS Group Forecasts Strong Price Appreciation for PACS Group (NYSE:PACS) Stock

PACS Group (NYSE:PACS) had its price target increased by equities researchers at UBS Group from $60.00 to $67.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group‘s target price indicates a potential upside of 34.86% from the company’s previous close.

Several other equities research analysts have also recently weighed in on PACS. Oppenheimer boosted their price target on shares of PACS Group from $48.00 to $57.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Royal Bank Of Canada increased their price objective on shares of PACS Group from $52.00 to $57.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Zacks Research cut shares of PACS Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 9th. Stephens boosted their target price on shares of PACS Group from $60.00 to $64.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Wall Street Zen downgraded shares of PACS Group from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $61.33.

PACS Group Price Performance

PACS Group stock traded down $0.52 during midday trading on Thursday, reaching $49.68. 874,681 shares of the stock traded hands, compared to its average volume of 816,441. The stock has a market cap of $7.86 billion, a P/E ratio of 28.07, a PEG ratio of 1.42 and a beta of -0.14. The stock’s fifty day moving average is $44.64 and its 200-day moving average is $40.03. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.21. PACS Group has a 12 month low of $10.31 and a 12 month high of $51.68.

PACS Group (NYSE:PACS) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.05. The business had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.46 billion. PACS Group had a return on equity of 29.55% and a net margin of 4.85%. As a group, equities research analysts anticipate that PACS Group will post 2.13 EPS for the current year.

Insider Buying and Selling

In other news, CAO Michelle Lewis sold 3,172 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $50.06, for a total value of $158,790.32. Following the sale, the chief accounting officer owned 340,338 shares of the company’s stock, valued at approximately $17,037,320.28. This represents a 0.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Hancock sold 186,696 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $50.45, for a total transaction of $9,418,813.20. Following the completion of the sale, the director owned 53,318,884 shares of the company’s stock, valued at $2,689,937,697.80. This trade represents a 0.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,762,431 shares of company stock worth $80,686,053 over the last three months. 70.10% of the stock is owned by insiders.

Hedge Funds Weigh In On PACS Group

Several hedge funds have recently bought and sold shares of the business. Eurizon Capital SGR S.p.A. bought a new position in shares of PACS Group in the third quarter worth about $34,000. Fulcrum Asset Management LLP lifted its holdings in PACS Group by 244.8% during the 3rd quarter. Fulcrum Asset Management LLP now owns 11,014 shares of the company’s stock valued at $465,000 after buying an additional 7,820 shares in the last quarter. Vise Technologies Inc. boosted its position in PACS Group by 40.6% in the 3rd quarter. Vise Technologies Inc. now owns 7,209 shares of the company’s stock valued at $300,000 after buying an additional 2,081 shares during the period. State of Wyoming boosted its position in PACS Group by 11.9% in the 3rd quarter. State of Wyoming now owns 10,551 shares of the company’s stock valued at $438,000 after buying an additional 1,119 shares during the period. Finally, Smith Group Asset Management LLC grew its stake in PACS Group by 1.3% in the 3rd quarter. Smith Group Asset Management LLC now owns 24,680 shares of the company’s stock worth $1,025,000 after acquiring an additional 320 shares in the last quarter.

Trending Headlines about PACS Group

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Quarterly results beat expectations and outlook rose. PACS reported Q3 EPS of $0.63 and revenue of $1.50 billion, topping estimates; adjusted EBITDA increased 33.6%. Management raised its 2026 revenue forecast to $5.95–$6.05 billion and adjusted EBITDA outlook to $685–$695 million. Q3 earnings coverage Raised 2026 outlook
• Positive Sentiment: Expansion and facility ramp-ups may support continued growth. Recent acquisitions in Florida and Texas, along with the Eduro deal, add about 8,400 beds. Company leaders cited occupancy near 90%, while newer facilities mature and move toward higher occupancy and patient acuity. Acquisitions and results Occupancy and acquisitions
• Positive Sentiment: Analysts raised targets and maintained bullish ratings. Truist lifted its target to $65 and kept Buy; Stephens raised its target to $64 with an Overweight rating. UBS also raised its target to $67 and maintained Buy. Truist target update Stephens forecast
• Negative Sentiment: Executives and a director disclosed stock sales. CEO Jason Murray and director Mark Hancock sold shares, as did the CAO. The transactions were made under pre-arranged Rule 10b5-1 plans, and the CEO and director retained substantial holdings, which may temper concerns. Director sale CEO sale

About PACS Group

PACS Group, Inc is a U.S.-based healthcare services company that owns and operates post-acute care facilities. Its platform focuses primarily on skilled nursing and transitional care, serving patients who require rehabilitation, recovery support, long-term care, and other services following hospitalization or acute medical treatment.

The company’s operations also include assisted living, independent living, and behavioral health services in select locations. Through its facilities and related healthcare capabilities, PACS Group provides services such as nursing care, physical and occupational therapy, speech therapy, medical treatment, and support for patients with complex or extended care needs.

Founded in 2013 and headquartered in Farmington, Utah, PACS Group serves communities across multiple U.S.